Cargando…

Multinuclear MRI in Drug Discovery

The continuous development of magnetic resonance imaging broadens the range of applications to newer areas. Using MRI, we can not only visualize, but also track pharmaceutical substances and labeled cells in both in vivo and in vitro tests. (1)H is widely used in the MRI method, which is determined...

Descripción completa

Detalles Bibliográficos
Autores principales: Bartusik-Aebisher, Dorota, Bober, Zuzanna, Zalejska-Fiolka, Jolanta, Kawczyk-Krupka, Aleksandra, Aebisher, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9572840/
https://www.ncbi.nlm.nih.gov/pubmed/36235031
http://dx.doi.org/10.3390/molecules27196493
_version_ 1784810717311926272
author Bartusik-Aebisher, Dorota
Bober, Zuzanna
Zalejska-Fiolka, Jolanta
Kawczyk-Krupka, Aleksandra
Aebisher, David
author_facet Bartusik-Aebisher, Dorota
Bober, Zuzanna
Zalejska-Fiolka, Jolanta
Kawczyk-Krupka, Aleksandra
Aebisher, David
author_sort Bartusik-Aebisher, Dorota
collection PubMed
description The continuous development of magnetic resonance imaging broadens the range of applications to newer areas. Using MRI, we can not only visualize, but also track pharmaceutical substances and labeled cells in both in vivo and in vitro tests. (1)H is widely used in the MRI method, which is determined by its high content in the human body. The potential of the MRI method makes it an excellent tool for imaging the morphology of the examined objects, and also enables registration of changes at the level of metabolism. There are several reports in the scientific publications on the use of clinical MRI for in vitro tracking. The use of multinuclear MRI has great potential for scientific research and clinical studies. Tuning MRI scanners to the Larmor frequency of a given nucleus, allows imaging without tissue background. Heavy nuclei are components of both drugs and contrast agents and molecular complexes. The implementation of hyperpolarization techniques allows for better MRI sensitivity. The aim of this review is to present the use of multinuclear MRI for investigations in drug delivery.
format Online
Article
Text
id pubmed-9572840
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95728402022-10-17 Multinuclear MRI in Drug Discovery Bartusik-Aebisher, Dorota Bober, Zuzanna Zalejska-Fiolka, Jolanta Kawczyk-Krupka, Aleksandra Aebisher, David Molecules Review The continuous development of magnetic resonance imaging broadens the range of applications to newer areas. Using MRI, we can not only visualize, but also track pharmaceutical substances and labeled cells in both in vivo and in vitro tests. (1)H is widely used in the MRI method, which is determined by its high content in the human body. The potential of the MRI method makes it an excellent tool for imaging the morphology of the examined objects, and also enables registration of changes at the level of metabolism. There are several reports in the scientific publications on the use of clinical MRI for in vitro tracking. The use of multinuclear MRI has great potential for scientific research and clinical studies. Tuning MRI scanners to the Larmor frequency of a given nucleus, allows imaging without tissue background. Heavy nuclei are components of both drugs and contrast agents and molecular complexes. The implementation of hyperpolarization techniques allows for better MRI sensitivity. The aim of this review is to present the use of multinuclear MRI for investigations in drug delivery. MDPI 2022-10-01 /pmc/articles/PMC9572840/ /pubmed/36235031 http://dx.doi.org/10.3390/molecules27196493 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Bartusik-Aebisher, Dorota
Bober, Zuzanna
Zalejska-Fiolka, Jolanta
Kawczyk-Krupka, Aleksandra
Aebisher, David
Multinuclear MRI in Drug Discovery
title Multinuclear MRI in Drug Discovery
title_full Multinuclear MRI in Drug Discovery
title_fullStr Multinuclear MRI in Drug Discovery
title_full_unstemmed Multinuclear MRI in Drug Discovery
title_short Multinuclear MRI in Drug Discovery
title_sort multinuclear mri in drug discovery
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9572840/
https://www.ncbi.nlm.nih.gov/pubmed/36235031
http://dx.doi.org/10.3390/molecules27196493
work_keys_str_mv AT bartusikaebisherdorota multinuclearmriindrugdiscovery
AT boberzuzanna multinuclearmriindrugdiscovery
AT zalejskafiolkajolanta multinuclearmriindrugdiscovery
AT kawczykkrupkaaleksandra multinuclearmriindrugdiscovery
AT aebisherdavid multinuclearmriindrugdiscovery